Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 374,100 shares, a decrease of 6.2% from the October 31st total of 398,900 shares. Based on an average daily volume of 136,800 shares, the short-interest ratio is presently 2.7 days.

Harvard Bioscience Price Performance

Shares of NASDAQ HBIO traded up $0.10 during midday trading on Tuesday, reaching $2.30. 84,735 shares of the company were exchanged, compared to its average volume of 119,977. The stock’s 50-day moving average price is $2.39 and its 200-day moving average price is $2.77. The stock has a market cap of $100.33 million, a P/E ratio of -6.67 and a beta of 1.27. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience has a one year low of $1.99 and a one year high of $5.56.

Hedge Funds Weigh In On Harvard Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the company. Harvey Partners LLC grew its holdings in shares of Harvard Bioscience by 6.2% during the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after purchasing an additional 157,500 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Harvard Bioscience by 193.9% in the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after acquiring an additional 150,218 shares during the last quarter. Acuitas Investments LLC lifted its holdings in Harvard Bioscience by 24.8% in the second quarter. Acuitas Investments LLC now owns 407,343 shares of the medical instruments supplier’s stock valued at $1,161,000 after buying an additional 80,827 shares during the period. Vanguard Group Inc. boosted its position in Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new stake in Harvard Bioscience during the 2nd quarter worth about $128,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.